Pharmacologic modulation of brain metabolism by valproic acid can induce a neuroprotective environment.

Abstract

OBJECTIVE:

Traumatic brain injury (TBI) is a leading cause of trauma-related morbidity and mortality. Valproic acid (VPA) has been shown to attenuate brain lesion size and swelling within the first few hours following TBI. Because injured neurons are sensitive to metabolic changes, we hypothesized that VPA treatment would alter the metabolic profile in the perilesional brain tissues to create a neuroprotective environment.

METHODS:

We subjected swine to combined TBI (12-mm cortical impact) and hemorrhagic shock (40% blood volume loss and 2 hours of hypotension) and randomized them to two groups (n = 5/group): (1) normal saline (NS; 3× hemorrhage volume) and (2) NS-VPA (NS, 3× hemorrhage volume; VPA, 150 mg/kg). After 6 hours, brains were harvested, and 100 mg of the perilesional tissue was used for metabolite extraction. Samples were analyzed using reversed-phase liquid chromatography-mass spectrometry in positive and negative ion modes, and data were analyzed using MetaboAnalyst software (McGill University, Quebec, Canada).

RESULTS:

In untargeted reversed-phase liquid chromatography-mass spectrometry analysis, we detected 3,750 and 1,955 metabolites in positive and negative ion modes, respectively. There were no significantly different metabolites in positive ion mode; however, 167 metabolite features were significantly different (p < 0.05) in the negative ion mode, which included VPA derivates. Pathway analysis showed that several pathways were affected in the treatment group, including the biosynthesis of unsaturated fatty acids (p = 0.001). Targeted amino acid analysis on glycolysis/tricarboxylic acid (TCA) cycle revealed that VPA treatment significantly decreased the levels of the excitotoxic amino acid serine (p = 0.001).

CONCLUSION:

Valproic acid can be detected in perilesional tissues in its metabolized form. It also induces metabolic changes in the brains within the first few hours following TBI to create a neuroprotective environment.

• Authors: Umar F Bhatti, Alla Karnovsky, Isabel S Dennahy, Maureen Kachman, Aaron M Williams, Vahagn C Nikolian, Ben E Biesterveld, Ali Siddiqui, Rachel L O'Connell, Baoling Liu, Yongqing Li, Hasan B Alam
• Journal: The journal of trauma and acute care surgery (J Trauma Acute Care Surg) Vol. 90 Issue 3 Pg. 507-514 (03 01 2021) ISSN: 2163-0763 [Electronic] United States
• PMID: 33196629 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Histone Deacetylase Inhibitors
• Valproic Acid

Topics

• Animals
• Brain Injuries, Traumatic (drug therapy, metabolism, pathology)
• Disease Models, Animal
• Female
• Histone Deacetylase Inhibitors (therapeutic use)
• Neuroprotection
• Shock, Hemorrhagic (drug therapy, metabolism, pathology)
• Swine
• Valproic Acid (therapeutic use)